These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35746673)

  • 1. Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations.
    Cilento ME; Ong YT; Tedbury PR; Sarafianos SG
    Viruses; 2022 May; 14(6):. PubMed ID: 35746673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
    Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
    Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
    D'Amico R; Cenoz Gomis S; Moodley R; Van Solingen-Ristea R; Baugh B; Van Landuyt E; Van Eygen V; Min S; Cutrell A; Foster C; Chilton D; Allard SD; Ruiter A
    HIV Med; 2023 Feb; 24(2):202-211. PubMed ID: 35945163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection.
    Ullah Nayan M; Sillman B; Hasan M; Deodhar S; Das S; Sultana A; Thai Hoang Le N; Soriano V; Edagwa B; Gendelman HE
    Adv Drug Deliv Rev; 2023 Sep; 200():115009. PubMed ID: 37451501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
    Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
    Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting drugs and formulations for the treatment and prevention of HIV infection.
    Flexner C; Owen A; Siccardi M; Swindells S
    Int J Antimicrob Agents; 2021 Jan; 57(1):106220. PubMed ID: 33166693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabotegravir/rilpivirine (Cabenuva) for HIV-1 infection.
    Med Lett Drugs Ther; 2021 May; 63(1625):81-83. PubMed ID: 34180282
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the
    Jeffrey JL; St Clair M; Wang P; Wang C; Li Z; Beloor J; Talarico C; Fridell R; Krystal M; White CT; Griffith S; D'Amico R; Smith K; Van Eygen V; Vingerhoets J; Vandermeulen K; Spreen W; van Lunzen J
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0170221. PubMed ID: 34978890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
    Garris CP; Czarnogorski M; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
    J Int AIDS Soc; 2022 Sep; 25(9):e26006. PubMed ID: 36097674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
    Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
    Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study.
    Parker B; Ward T; Hayward O; Jacob I; Arthurs E; Becker D; Anderson SJ; Chounta V; Van de Velde N
    PLoS One; 2021; 16(2):e0245955. PubMed ID: 33529201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
    Overton ET; Richmond G; Rizzardini G; Jaeger H; Orrell C; Nagimova F; Bredeek F; García Deltoro M; Swindells S; Andrade-Villanueva JF; Wong A; Khuong-Josses MA; Van Solingen-Ristea R; van Eygen V; Crauwels H; Ford S; Talarico C; Benn P; Wang Y; Hudson KJ; Chounta V; Cutrell A; Patel P; Shaefer M; Margolis DA; Smith KY; Vanveggel S; Spreen W
    Lancet; 2021 Dec; 396(10267):1994-2005. PubMed ID: 33308425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
    Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR
    Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
    Gaur AH; Capparelli EV; Calabrese K; Baltrusaitis K; Marzinke MA; McCoig C; Van Solingen-Ristea RM; Mathiba SR; Adeyeye A; Moye JH; Heckman B; Lowenthal ED; Ward S; Milligan R; Samson P; Best BM; Harrington CM; Ford SL; Huang J; Crauwels H; Vandermeulen K; Agwu AL; Smith-Anderson C; Camacho-Gonzalez A; Ounchanum P; Kneebone JL; Townley E; Bolton Moore C; ;
    Lancet HIV; 2024 Apr; 11(4):e211-e221. PubMed ID: 38538160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No antagonism or cross-resistance and a high barrier to the emergence of resistance
    Diamond TL; Goh SL; Ngo W; Rodriguez S; Xu M; Klein DJ; Grobler JA; Asante-Appiah E
    Antimicrob Agents Chemother; 2024 Jul; 68(7):e0033424. PubMed ID: 38864613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection.
    Zeuli JD; Rivera CG; Smith BL; Otto A; Temesgen Z
    Drugs Today (Barc); 2022 Dec; 58(12):555-576. PubMed ID: 36651065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection.
    Dzinamarira T; Almehmadi M; Alsaiari AA; Allahyani M; Aljuaid A; Alsharif A; Khan A; Kamal M; Rabaan AA; Alfaraj AH; AlShehail BM; Alotaibi N; AlShehail SM; Imran M
    Medicina (Kaunas); 2023 May; 59(6):. PubMed ID: 37374245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting combination of cabotegravir plus rilpivirine: A picture of potential eligible and ineligible HIV-positive individuals from the Italian ARCA cohort.
    Cervo A; Russo A; Di Carlo D; De Vito A; Fabeni L; D'Anna S; Duca L; Colpani A; Fois M; Zauli B; Mancarella G; Carraro A; Bezenchek A; Cozzi-Lepri A; Santoro MM;
    J Glob Antimicrob Resist; 2023 Sep; 34():141-144. PubMed ID: 37453495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study.
    Bettonte S; Berton M; Stader F; Battegay M; Marzolini C
    Clin Infect Dis; 2023 Apr; 76(7):1225-1236. PubMed ID: 36377436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.